Ping An Biomedical Acquires Tumor Cell Patents for $2.3M

Ping An Biomedical Co., Ltd. announced the acquisition of three tumor cell-related medical technology patents from Future Biotechnology Group Co., Limited for an aggregate consideration of $2.3 million. The acquired patents cover areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies. This acquisition is intended to bolster the company's longer-term healthcare and biomedical research and development strategy and establish a core intellectual property portfolio in oncology and biotechnology. Separately, Ping An Biomedical continues to advance negotiations regarding its proposed strategic investment in Future Biotechnology Group Co., Limited.